Business Today
Subscribe
PMS TodayUS NewsIndiaUPSTARTWeatherBT ShortsNRIEducationElection
BT GolfBT MindrushBT Best Banks
Search

COMPANIES

No Data Found

NEWS

No Data Found
Advertisement
News
markets
stocks
Syncom Formulations (India) Ltd
Syncom Formulations (India) Ltd

Syncom Formulations (India) Ltd (SYNCOMF) Share Price

  • Sector: Pharmaceuticals (Small Cap)
  • Volume: 19,05,580
May 09, 2025 Closed
  • NSE
  • BSE
Share
  • Whatsapp
  • Twitter
  • Facebook
₹15.10
₹-0.38 (-2.45%)
14.73Low
Today’s Performance
15.33High
10.95Low
52 Week’s Performance
27.90High

bt_logoStock Analysis

bt_logoStock Performance

  • 1 Day-2.45%
  • 1 Week-6.44%
  • 1 Month-7.53%
  • 3 Months-16.20%
  • 6 Months-24.80%
  • 1 Year16.60%
  • 3 Years23.07%
  • 5 Years-%

bt_logoPeer Comparison

Syncom Formulations (India) Ltd
Sun Pharmaceutical Industries Ltd
Divis Laboratories Ltd
Cipla Ltd
Price

₹15.10

Syncom Formulations (India) Ltd

₹1,744.80

Sun Pharmaceutical Industries Ltd

₹6,025.50

Divis Laboratories Ltd

₹1,480.00

Cipla Ltd

bt_logoStock Summary

  • Face Value (₹)1.00
  • Beta1.20
  • 52-Week Low (₹)10.95
  • 52-Week High (₹)27.90
  • Price-to-Book (X)*4.51
  • Dividend Yield (%)-
  • Price-to-Earnings (P/E) (X)*35.83
  • Earnings Per Share (₹)0.42
  • Market Cap (₹ Cr.)*1,419.40
* Values as of last close price

bt_logoCOMPETITORS

BT TV

SIPs Continue Despite Rising Indo-Pak Tensions, Are Average Investors Clueless About War Risk?1:36SIPs Continue Despite Rising Indo-Pak Tensions, Are Average Investors Clueless About War Risk?
Niranjan Hiranandani: "Real Estate Has Grown By Almost 15 Percent While Gdp In India Has Grown By 6.5 To 7 Percent"13:46Niranjan Hiranandani: Why Affordable Housing Lags & Cities Set For Real Estate Boom
TIME TO INVEST IN DEFENCE STOCKS?0:56Indo-Pak Tensions | Samir Arora Explains Why Defense Stocks Could Be The Next Big Opportunity
WILL THE TARIFF PAUSE BE EXTENDED?1:19India's Trade Talks with U.S.: Is a 90-Day Tariff Pause Extension on the Horizon?
SAMIR ARORA’S RED FLAG ON FMCG SECTOR!0:53Samir Arora Flags Low Growth In Consumer Staples Amid Rising Unlisted Competition
After Nearly 100 Hours Of Hostilities With Pakistan, India Announces Ceasefire Effective 5 pm, May 1After Nearly 100 Hours Of Hostilities With Pakistan, India Announces Ceasefire Effective 5 pm, May 10:55After Nearly 100 Hours Of Hostilities With Pakistan, India Announces Ceasefire Effective 5 pm, May 1
Pakistan’s Desperate Damage Control: From ‘All Drones Shot Down’ To ‘It Was Part Of The Plan’3:26Pakistan’s Desperate Damage Control: From ‘All Drones Shot Down’ To ‘It Was Part Of The Plan’
Pakistan’s Cowardly Blitz: Temples, Homes, And Civilians Targeted Across India’s Border States6:15Pakistan’s Cowardly Blitz: Temples, Homes, And Civilians Targeted Across India’s Border States
Civilian Planes As Shields? India Slams Pakistan’s Dangerous Drone Warfare Tactics3:55Civilian Planes As Shields? India Slams Pakistan’s Dangerous Drone Warfare Tactics
Operation Sindoor: PM Modi's Fiercest Retaliation Against Terror—A Mission Led By Heroes4:24Operation Sindoor: PM Modi's Fiercest Retaliation Against Terror—A Mission Led By Heroes
View more

bt_logoFinancial Analysis

Income Statement (₹ Cr.)
Balance Sheet (₹ Cr.)
Cash Flow (₹ Cr.)

bt_logoRatio Analysis

Return on Equity (%)
Return on Assets (%)
Price-to-Earnings (P/E) (X)
Price to Book (x)
Return on Capital Employed (%)
Enterprise Value to EBITDA (X)
Net Profit Margin (%)
Gross Profit Margin (%)
EBITDA Margin (%)

bt_logoShare Holding Pattern

Summary (As on 31 Mar 2025)
Promoters (50.57%)
Domestic institutional investors (0.00%)
Foreign Institutional Investors (1.86%)
Public & Others (46.55%)
Government Holding (0.00%)
Corporate Holding (1.02%)

bt_logoDeals

25 Sep, 2017SELL
SAMIR NARENDRA GUPTA
Qty2000000
Average Price₹1.46
25 Sep, 2017BUY
NARENDRAKUMAR BHAGWANDAS GUPTA
Qty2000000
Average Price₹1.46
30 Jan, 2015BUY
ALACRITY SECURITIES LIMITED
Qty500000
Average Price₹5.8
30 Jan, 2015SELL
ODYSSEY CORPORATION LIMITED
Qty500000
Average Price₹5.8
03 Feb, 2014BUY
SUNITA MOTILAL SINHA
Qty543750
Average Price₹5.5
03 Feb, 2014SELL
KIRIT VASUDEO DAVE
Qty543750
Average Price₹5.5
*Single trade that involves transaction of a minimum quantity of 5 lakh shares or a minimum value of ₹ 10 crore.

bt_logoFAQ's

What was Syncom Formulations (India) Ltd share price previously?
Syncom Formulations (India) Ltd share price was down by -2.45% from the previous closing price of ₹15.48.
Who are peers of Syncom Formulations (India) Ltd?
The peers of Syncom Formulations (India) Ltd are Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Cipla Ltd, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Dr Reddys Laboratories Ltd, Lupin Ltd.
Who is/are the promoter/promoters of Syncom Formulations (India) Ltd?
The promotor/promotors of Syncom Formulations (India) Ltd are Kedarmal Bankda, Vijay Shankarlal Bankda, Rinki Bankda, Ruchi Jindal, Vaishali Agrawal, Ritesh Kumar Lunkad, Ankit Jain.
What has been 52-week high of Syncom Formulations (India) Ltd stocks?
The highest price of Syncom Formulations (India) Ltd stock is ₹27.90 in the last 52-week.
What is the share price of Syncom Formulations (India) Ltd (SYNCOMF) today on NSE?
As on May 09, 2025 Syncom Formulations (India) Ltd (SYNCOMF)’s share price on NSE is Rs 15.1
What is the market cap of Syncom Formulations (India) Ltd (SYNCOMF)?
The current market capitalisation of Syncom Formulations (India) Ltd (SYNCOMF) is 1,419.40 crores
What is Syncom Formulations (India) Ltd Share symbol?
The symbol of Syncom Formulations (India) Ltd is SYNCOMF.
What is the PE ratio of Syncom Formulations (India) Ltd (SYNCOMF)?
The current PE ratio of Syncom Formulations (India) Ltd (SYNCOMF) is 35.83.
What is the PB ratio of Syncom Formulations (India) Ltd (SYNCOMF)?
The current PB ratio of Syncom Formulations (India) Ltd (SYNCOMF) is 4.51.
Today’s High & Low share prices of Syncom Formulations (India) Ltd (SYNCOMF) on NSE?
Today, the share price of Syncom Formulations (India) Ltd (SYNCOMF) on NSE touched a high of Rs 15.33 and a low of Rs 14.73
What price did Syncom Formulations (India) Ltd (SYNCOMF) shares open on the NSE today?
On NSE, the share price of Syncom Formulations (India) Ltd (SYNCOMF) opened at Rs 15
What is the 52-week high of Syncom Formulations (India) Ltd (SYNCOMF)?
The 52-week high price of Syncom Formulations (India) Ltd (SYNCOMF) is Rs 27.90
What is the 52-week low of Syncom Formulations (India) Ltd (SYNCOMF)?
The 52-week low price of Syncom Formulations (India) Ltd (SYNCOMF) is Rs 10.95

bt_logoAbout Syncom Formul.

Syncom Formulations (India) Ltd, incorporated in the year 1988, has its registered office in 7 Niraj Indl Estate Andheri(E), Off Mahakali Caves Rd, Mumbai, Maharashtra, 400093, 91-22-30887744, 91-22-30887755. The main industry in which Syncom Formulations (India) Ltd operates is Pharmaceuticals - Indian - Formulations.

Auditor/Auditors for Syncom Formulations (India) Ltd is/are Sanjay Mehta & Associates. In the main management, Kedarmal Bankda is chairman and Vaishali Agrawal is the company secretary for Syncom Formulations (India) Ltd.

  • KB
    Kedarmal BankdaChairman & Wholetime Director
  • VSB
    Vijay Shankarlal BankdaManaging Director
  • RB
    Rinki BankdaWhole-time Director
  • RJ
    Ruchi JindalIndependent Director
  • VA
    Vaishali AgrawalCompany Sec. & Compli. Officer
  • RKL
    Ritesh Kumar LunkadIndependent Director
  • AJ
    Ankit JainIndependent Director

bt_logoTop Stories

DATA SOURCES: Corporate data, historical price & volume data published on this website have been sourced from CMOTS Internet Technologies Pvt. Ltd. BSE Quotes and NSE Quotes have been sourced from BSE Limited and NSE Data & Analytics Limited, respectively. All timestamps reflected here are in IST (Indian Standard Time). Stock Analysis section has been sourced from the mentioned partners.

DISCLAIMER: Any and all content on this website, including the tools/ analysis, is provided to you only for convenience and on an “as-is, as-available” basis without representation and warranties of any kind. The content and any output of such tools/ analysis is for informational purposes only and should not be relied upon or construed as investment advice or guarantee for any specific performance/ returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this website, you agree to the Terms of Service and Privacy Policy.